MX2021007939A - Porciones de union a claudina 18.2 y usos de estas. - Google Patents

Porciones de union a claudina 18.2 y usos de estas.

Info

Publication number
MX2021007939A
MX2021007939A MX2021007939A MX2021007939A MX2021007939A MX 2021007939 A MX2021007939 A MX 2021007939A MX 2021007939 A MX2021007939 A MX 2021007939A MX 2021007939 A MX2021007939 A MX 2021007939A MX 2021007939 A MX2021007939 A MX 2021007939A
Authority
MX
Mexico
Prior art keywords
binding moieties
claudin
chimeric antigen
antigen receptors
engineered immune
Prior art date
Application number
MX2021007939A
Other languages
English (en)
Inventor
Yong Liu
Xiaohu Fan
Qiuchuan Zhuang
Dan Zhao
Liusong Yin
Tielin Zhou
Zhuo Fang
Bo Wu
Qingshan Zhang
Jie Mao
Original Assignee
Nanjing Genscript Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Genscript Biotech Co Ltd filed Critical Nanjing Genscript Biotech Co Ltd
Publication of MX2021007939A publication Critical patent/MX2021007939A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En el presente documento se describen porciones de unión, tales como anticuerpos, que se unen específicamente a claudina 18.2, y receptores de antígeno híbrido que comprenden tales porciones de unión. Además, se proporcionan células inmunitarias genomanipuladas (tales como linfocitos T) que comprenden receptores de antígeno híbrido contra la claudina 18.2. También se describen métodos de tratamiento de tumores o cánceres que expresan claudina 18.2 mediante el uso de las porciones de unión, los receptores de antígeno híbrido y las células inmunitarias genomanipuladas.
MX2021007939A 2018-12-28 2019-12-27 Porciones de union a claudina 18.2 y usos de estas. MX2021007939A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018125052 2018-12-28
CN2019095827 2019-07-12
PCT/CN2019/129017 WO2020135674A1 (en) 2018-12-28 2019-12-27 Claudin18.2 binding moieties and uses thereof

Publications (1)

Publication Number Publication Date
MX2021007939A true MX2021007939A (es) 2021-10-22

Family

ID=71127698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007939A MX2021007939A (es) 2018-12-28 2019-12-27 Porciones de union a claudina 18.2 y usos de estas.

Country Status (12)

Country Link
US (1) US20220073643A1 (es)
EP (1) EP3902839A4 (es)
JP (1) JP2022515487A (es)
KR (1) KR20210110339A (es)
CN (1) CN113227146B (es)
AU (1) AU2019415848A1 (es)
BR (1) BR112021012608A2 (es)
CA (1) CA3125193A1 (es)
IL (1) IL284393A (es)
MX (1) MX2021007939A (es)
SG (1) SG11202106534RA (es)
WO (1) WO2020135674A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113637082A (zh) * 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
EP4217396A1 (en) * 2020-09-28 2023-08-02 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-claudin18 antibodies
IL302402A (en) 2020-11-08 2023-06-01 Seagen Inc Combined treatment
CN114539402A (zh) * 2020-11-27 2022-05-27 南京北恒生物科技有限公司 靶向Claudin18.2的抗体及其用途
CA3199212A1 (en) * 2020-11-27 2022-06-02 Junji DONG Cldn18.2 antibody and use thereof
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
MX2023007644A (es) 2020-12-23 2023-07-07 Sotio Biotech A S Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2.
CN113321730B (zh) * 2021-01-11 2023-10-10 上海莱馥医疗科技有限公司 Cldn18.2抗体及其应用
WO2022166940A1 (en) * 2021-02-08 2022-08-11 Shandong Boan Biotechnology Co., Ltd. Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors
CN115109154A (zh) * 2021-03-17 2022-09-27 三优生物医药(上海)有限公司 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
WO2024096564A1 (ko) * 2022-11-01 2024-05-10 앱티스 주식회사 항-클라우딘18.2 항체를 포함하는 항체-약물 컨쥬게이트 및 이의 암에 대한 치료용도
CN116284224B (zh) * 2023-05-12 2023-07-25 中国农业大学 一种结合Claudin 18.2的环肽及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN105315375B (zh) * 2014-07-17 2021-04-23 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
KR20190038564A (ko) * 2016-07-08 2019-04-08 카르스젠 테라퓨틱스 컴퍼니, 리미티드 항클라우딘 18a2의 항체 및 이의 응용
SG10202111141WA (en) * 2018-05-18 2021-11-29 Lanova Medicines Ltd Company Anti-claudin 18.2 antibodies and uses thereof
US11407828B2 (en) * 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
MX2022002111A (es) * 2019-08-20 2022-03-17 Suzhou Transcenta Therapeutics Co Ltd Novedosos anticuerpos anti-cldn18.2.

Also Published As

Publication number Publication date
EP3902839A1 (en) 2021-11-03
CA3125193A1 (en) 2020-07-02
AU2019415848A1 (en) 2021-08-19
CN113227146A (zh) 2021-08-06
JP2022515487A (ja) 2022-02-18
CN113227146B (zh) 2024-03-01
BR112021012608A2 (pt) 2021-09-08
EP3902839A4 (en) 2022-12-14
US20220073643A1 (en) 2022-03-10
AU2019415848A8 (en) 2021-09-02
IL284393A (en) 2021-08-31
SG11202106534RA (en) 2021-07-29
KR20210110339A (ko) 2021-09-07
WO2020135674A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
MX2021007939A (es) Porciones de union a claudina 18.2 y usos de estas.
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
MX2019006598A (es) Celulas asesinas naturales modificadas geneticamente y sus usos.
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
PH12019502637A1 (en) Chimeric antigen receptors targeting flt3
MX2020012927A (es) Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular.
PH12020551671A1 (en) Chimeric receptors to dll3 and methods of use thereof
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
MY194997A (en) Anti-ccr7 antibody drug conjugates
MX2020002036A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.
AU2018338423A1 (en) Novel anti-HLA-A2 antibodies and uses thereof
PH12021550120A1 (en) Chimeric receptors to steap1 and methods of use thereof
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
MX2020001257A (es) Proteinas que se unen a nkg2d, cd16 y flt3.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células
CR20210548A (es) Materiales y métodos para modular la inmunidad mediada por células t
EA202191821A1 (ru) Группы, связывающие клаудин 18.2, и их использование
MX2020013923A (es) Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.